GAMMAKED HAS BEEN PROVEN EFFECTIVE FOR THE
TREATMENT OF CIDP, PI AND ITP1
Patients with CIDP show significant improvement when treated with GAMMAKED
In a clinical study with 117 subjects with CIDP, those treated with GAMMAKED showed significantly improved disability scores compared to those given an inactive substance (placebo).
Also, more than 87% of patients given GAMMAKED every 3 weeks maintained these improvements and did not relapse during the extension phase, compared to 55% patients given placebo.2
GAMMAKED is proven to protect against infections in patients with PI
Most people with a primary immunodeficiency disorder suffer from frequent, and often severe, sinus infections.3 That's why a reduced number of sinus infections is a great indicator that your therapy is working effectively.
In a clinical study with 172 patients with primary humoral immunodeficiency, GAMMAKED demonstrated protection from severe infections and acute sinusitis.4
GAMMAKED doubled the platelet count in chronic ITP
Patients with chronic ITP have low blood platelet counts.5
In a clinical study with 97 adults and children with ITP, GAMMAKED treatment resulted in a doubling of platelet counts in 90% of subjects by the 7th day after completing treatment compared to 83% of patients receiving another ITP treatment.6
ASK YOUR HEALTHCARE PROFESSIONAL IF GAMMAKED IS RIGHT FOR YOU
References: 1. GAMMAKED [prescribing information]. Fort Lee, NJ: Kedrion Biopharma; 2018. 2. Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate/chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136-44. 3. Ten warning signs of primary immunodeficiency. The Jeffrey Modell Foundation Website. http://www.info4pi.org/library/educational-materials/10-warning-signs. Accessed April 2, 2019. 4. Roifman CM, Schroeder H, Berger M., et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency: A randomized double-blind trial. Int Immunopharmacol. 2003;3:1325-33. 5. Provan D, Stasi R, Newland AC, et al. International consensus report on investigation and management of immune thrombocytopenia. Blood. 2010;115:168-86. 6. Bussell JB, Eldor A, Kelton JG, et al. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action and impact on quality of life. Thromb Haemost. 2004;91:771-8.